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nism in Heart Failure Outcome Study with Tolvaptan (EVEREST) trial showed that
tolvaptan, combined with standard therapy, improved many heart failure signs
and symptoms without serious adverse events. This study evaluated the hospital
resource utilization associated with tolvaptan usage among heart failure (HF) pa-
tients with hyponatremia based on the EVEREST trial. METHODS: A cost offset
model was constructed to evaluate the impact of tolvaptan on hospital resource
utilization among HF patients. The Healthcare Cost and Utilization Project (HCUP)
2008 Nationwide Inpatient Sample (NIS) database was used to estimate hospital-
ization length of stay (LOS) and hospital cost, for HF-associated diagnosis related
group hospitalizations (DRG) of adult patients (age 18 years). EVEREST trial data
for patients with hyponatremia were used to estimate the reduction of LOS asso-
ciatedwith tolvaptan vs. placebo. RESULTS:Among EVEREST trial HF patients with
hyponatremia (135 mEq/L), tolvaptan patients had a shorter hospitalization LOS
than placebo patients (9.72 vs. 11.44 days, respectively), with a relative LOS reduc-
tion of 15%. 933,189 HF-associated DRG hospitalizations were identified from the
HCUP NIS database. The mean LOS was 4.8 days with mean total hospital costs of
$7,545, andmean daily hospital costs of $1,562. Using an inpatient tolvaptan treat-
ment duration of 3 days with a daily wholesale acquisition cost of $250, the cost
offset model estimated a LOS reduction among US HF hospitalizations of 0.73 days
with a hospital cost reduction averaging $1,134 per HF admission. The cost neutral
breakeven mean duration of tolvaptan inpatient therapy is 4.54 days.
CONCLUSIONS: Based on the EVEREST trial, tolvaptan is associated with a shorter
hospitalization LOS than placebo among hyponatremic HF patients, resulting in an
estimated mean hospital cost reduction of $1,134 per admission in the US.
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OBJECTIVES: Anti-platelet therapy is recommended for patients with a history of
acute coronary syndrome (ACS), including aspirin and clopidogrel or prasugrel.
Ticagrelor is a new anti-platelet agent, not yet available on the market; in clinical
trials ticagrelor was associated with significantly higher rates of dyspnea than
clopidogrel. ACS patients presenting with dyspnea require additional medical at-
tention to rule out possible heart failure which may lead to increased costs. This
study used real world data to quantify the direct medical costs of dyspnea among
patients with a history of ACS. METHODS: Patients with an emergency room (ER)
visit for dyspnea (ICD-9-CM 786.0x) in 2008 or 2009 were identified using the Mar-
ketScan Research Databases®. Patients were required to have six months contin-
uous medical enrollment prior to the ER visit, with a history of ACS (ICD-9-CM
410.xx, 411.1x). Procedure utilization and expenditures were evaluated for the ER
visit and associated outpatient services, aswell as the proportion of ER visits which
led to an inpatient stay. Costs were adjusted to 2009 US dollars. RESULTS:A total of
8,433 ER visits for dyspnea were identified. The average cost per dyspnea episode
was $6,958, of which $1,621 was outpatient costs associated with the ER visit (SD
$3,269). Along with physician services, assessment of dyspnea often included elec-
trocardiogram (71.3%), chest radiograph (75.9%) and, occasionally, a B-type natri-
uretic peptide (BNP) test (14.9%) or chest CAT scan (12.2%). These procedures con-
stituted 35.1% of the average outpatient costs. Over a quarter (25.8%) of dyspnea ER
visits led to an inpatient stay, with an average cost of $20,693 per patient.
CONCLUSIONS: Dyspnea is a significant event associated with high medical re-
source utilization and hospital costs. Considering that the increased risk of dys-
pnea for ticagrelor is well-documented, these costs may be important to health
plan decision makers when evaluating costs associated with each anti-platelet
therapy.
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OBJECTIVES: The economic burden of stroke is approximately 3% of total health-
care costs or 0.3-1.8% of Gross National Product in developed countries. Identifying
what drives value and cost in post-stroke care can advance development of cost-
effective interventions that improve long term outcomes. This review character-
izes costs associated with stroke rehabilitation.METHODS: PUBMEDwas searched
between 2000 and 2010; search terms included stroke, rehabilitation, costs, phar-
macoeconomic and price. Countries of interest were Canada, China, France, Ger-
many, Italy, Japan, Spain, UK, and US. Data were synthesized qualitatively.
RESULTS:Of 941 abstracts, 28met inclusion criteria. Manual searching of retrieved
papers and websites yielded 4 additional sources. The main factor determining
costwas the country inwhich the studywas conducted. Patientswith severe stroke
are routinely considered for rehabilitation; those with mild-moderate stroke (60–
75% of stroke survivors) are typically discharged directly to home. Of all stroke
patients, only 10-15% receive rehabilitation. Countries spending a large proportion
on long term care for patients post-stroke, spent proportionally less on inpatient
care. Inpatient costs account for an average of 76% of costs in the first year follow-
ing stroke. Rehabilitation costs are often included in inpatient costs, with the ma-
jority of rehabilitation costs occurring in year 1 (82% for patients with hemiparesis;
67% for patients without hemiparesis). Evidence suggests that stroke unit care
improves long term outcomes as compared to conventional treatment. There are
few data on indirect costs despite the recognition that they are likely to be
substantial. CONCLUSIONS: Cost studies in stroke are heterogeneous, lack specific
economic data and rarely include long term rehabilitation cost of care. Future
studies should aim to differentiate 1) direct costs of various rehabilitation services,
2) location for provision of rehabilitation services, and 3) indirect costs to demon-
strate cost-effectiveness and value of rehabilitation on long term outcomes.
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OBJECTIVES: To evaluate typical practice and cost of treatment patients with acute
ischemic stroke in leading medical hospitals in Russia, to compare treatment pat-
terns and cost of treatment in “real world settings” and according to national
standard of care in stroke. METHODS: Retrospective analysis of case records of
patients with acute ischemic stroke. Treatment patterns in “real world settings”
and according to national standard of care in stroke were compared. Direct cost of
treatment was estimated from state health care system point of view. RESULTS:
Data from 140 case records was retrieved. Significant inconsistencies in the list of
medicines between protocol of care and typical practice have been identified. Par-
ticularly, the frequency prescription of anticonvulsants and myorelaxants in real
world settings was lower than in protocol. Low frequency of psychological (0%- in
typical practice, 80% - in protocol) and rehabilitation methods of treatment (33% -
in typical practice, 70-80% - in protocol) was revealed. Patients also didn’t receive
prophylactics of tromboembolism (6% - in typical practice, 80% - in protocol). Av-
erage total cost of treatment of one patient with ischemic stroke in typical practice
was 905 dollars (302 dollars – cost of drug therapy, 187 dollars – cost of medical
diagnostic and therapeutic services, 416 dollars – accommodation costs). Average
period of inpatient staywas 20 days. Average total cost of treatment of one patients
with ischemic stroke according to the protocol was 1 446 dollars (322 dollars – cost
of drug therapy, 686 dollars – cost of diagnostic and therapeutic services, 438 dol-
lars - accommodation costs). CONCLUSIONS: Significant inconsistencies of man-
agement patterns in patients with ischemic stroke in typical practice and national
standard have been revealed. Direct costs of inpatient care in typical practice are
approximately twice lower than costs calculated from national protocol of care.
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OBJECTIVES: To estimate the societal monetary benefit of simvastatin to three
separate groups: 1) developing manufacturer (DM), 2) generic manufacturer (GM)
and 3) society.METHODS:Themonetary benefits for DMandGMwere estimated by
calculating annual revenues based on IMS sales data between 2000 and 2009. We
used a dynamic Markov model to estimate the monetary benefits for society over
the same time period in terms of cost avoidance associated with prevented cardio-
vascular events including stroke and myocardial infarction and lost productivity
due to disability and premature death in the working population. Input estimates
for dynamic populations were derived from the IMS sales data. Input estimates for
prevented adverse events and costs were derived from systematic review and
meta-analysis when possible. Input estimates for reduction in health care utiliza-
tion and disability dayswere estimated frommultivariate regressions using data in
the 2005 Canadian Community Health Survey. All costs and benefits were ex-
pressed in 2010 Canadian dollars. RESULTS: The cumulative societal monetary
benefit of simvastatin over the 10 years (from 2000 to 2009) was estimated at $4
billion. Of this, DM accounted for 23%, GM 31%, and society 46% (health care 34%
and productivity losses 12%). Of note, the trend was different among the three
parties. The benefit to DM levelled out from 2002 when the pharmaceutical was no
longer under patent protection when the benefit to GM started to increase. The
benefit to society increased consistently over the study period.CONCLUSIONS:The
results indicate that simvastatin is associated with significant benefit to both society
and industry, including DM and GM. A comprehensive evaluation of benefits of phar-
maceutical innovation should therefore consider benefits to all beneficiaries.
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OBJECTIVES: To evaluate the cost-effectiveness of prasugrel versus clopidogrel, in
combination with aspirin, in patients undergoing planned percutaneous coronary
intervention (PCI) from the healthcare provider’s perspective in the United States.
METHODS: Second-order Monte Carlo simulation was conducted using TreeAge
Pro (2009) following the ISPOR task force guidelines for modeling. Model branches
included PCI type (bare metal stent and drug eluting stent), CYP2C19 polymor-
phisms, and clinical outcomes. Model inputs such as costs (2009 dollar value),
age-adjusted quality of life, and probabilities were identified through systematic
literature review. All future costs and QALYs were discounted by 5%. Life expec-
tancy was estimated using declining exponential approximation of life expectancy
(DEALE)method. Acceptability curvewas plotted to determine themost cost-effec-
tive strategy at various willingness-to-pay (WTP) thresholds ($0-$250,000/QALY).
One-way sensitivity analyses were performed to determine if the model was sen-
sitive to variation in probabilities, costs and disutilities associatedwithmyocardial
infarction (MI), stroke and major bleeding. RESULTS: Clopidogrel therapy resulted
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in lifetime costs and utilities of $17,208 and 10.4124 QALYs compared with $16,780
and 10.4057 QALYs for prasugrel therapy. The ICER for clopidogrel was $63,840/
QALYs. The acceptability curve showed that prasugrel was not likely cost-effective
with 80% certainty at any WTP threshold. One-way sensitivity analyses (WTP
decision threshold: $100,000/QALY) showed that prasugrel is the most cost-effec-
tive strategy when probability of MI is increased by12%, probability of bleeding is
decreased by 24%, and disutility associated with MI is 0.1634. When only pa-
tients with variant CYP2C19 were considered, the ICER was found to be $2,313,333/
QALY for clopidogrel. CONCLUSIONS: Inconclusive results indicate that there is no
benefit in prescribing one therapy over the other for the entire patient population.
CYP2C19 polymorphism should be given consideration during the decisionmaking
process. For the base-case scenario, prasugrel therapywas the preferred strategy in
patients with variant CYP2C19.
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OBJECTIVES: To evaluate the cost-effectiveness of rivaroxaban compared with
dabigatran and enoxaparin for the prophylaxis of venous thromboembolism in
patients undergoing elective total hip replacement (THR) in the context of Russian
health care system.METHODS: A decision-tree model on the choice of regimens
for thromboprophylaxis after THR was adopted from the model, developed by
McCullagh et. al. (2009). Primary outcomes was mortality, occurrence of distal and
proximal DVT, rates of symptomatic PE. Incidence of gastrointestinal bleeding,
stroke and death was also included into the model. Delphi method was used to
determine typical practice and cost ofmanagement of DVT and PE. It was assumed
that patients with DVTwere treated for 90 days, patients with PE – for 180 days. All
patients in the model received thromboprophylaxis with one of the following reg-
imens: rivaroxaban dose of 10 mg/day orally for 31-39 days (RECORD 2); dabigatran
dose of 220 mg/day orally for 28-35 days (RE-NOVETE); enoxaparin dose of 40 mg/
day subcutaneously for 10-14 days (RECORD 2). Incremental cost-effectiveness ra-
tios (ICERs) were calculated. RESULTS: The cost of prophylaxis with enoxaparin
was 6991 USD, with dabigatran - 7076 USD, with rivaroxaban - 7147 USD. Although
rivaroxaban has more effectiveness in preventing DVT (0.016 vs. 0.082 vs. 0.045)
and PE (0.0012 vs. 0.005 vs. 0.004) than enoxaparin and dabigatran correspondingly.
ICER to prevent 1 case of deep vein thrombosis after THR in rivaroxaban versus
enoxaparin was 23.6 USD, and in dabigatran versus enoxaparin was 22.9 USD. ICER
to prevent 1 case of pulmonary thromboembolism after THR in rivaroxaban versus
enoxaparin was 556.7 USD, and in dabigatran versus enoxaparin was 850.3 USD.
CONCLUSIONS: Despite of higher cost of prophylaxis of DVT and PE with rivaroxa-
ban, comparing to enoxaparin and dabigatran, prophylaxis with rivaroxaban was
more effective with acceptable ICERs.
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OBJECTIVES: New medicines are launched based on a limited number of clinical
trials. Payers, providers, and patients base their utilization decisions on this infor-
mation. Furthermore, projected cost-effectiveness and real world cost-effective-
ness are moving targets that may differ greatly, especially early in the product life
cycle.We examine this divergence using clopidogrel, an antiplateletmedication for
preventing strokes and heart attacks, as a case study. METHODS: Using the Na-
tional Ambulatory Medical Care Survey (NAMCS) data from 1998 to 2008, we esti-
mate changes in the volume and distribution of patient prescriptions by age,
gender, and race. We combine these time trends with estimates from the
pharmacoeconomics literature on cost-effectivenessmeasured as cost per quality-
adjusted life year (QALYs). RESULTS: From 1998 (following approval in November
1997) to 2001, the average age of clopidogrel patients dropped from 77 to 70. Over
the same period, the percentage of patients who were under 54 years of age in-
creased from 0% to 13%. Comparing the real-world patient population to a pivotal
phase 3 trial also reveals a large difference in gender mix: 72% male in the trial vs.
45% in NAMCS in 1998. Similar trends were found for race: by 2008, patients were
much less likely to be white than in the trial—only 82% versus 95%. In 1999, 1.7
million office visits included a prescription for clopidogrel, 7.5 times as many as in
1998. By 2008, almost 16million prescriptionswerewritten—1.5 for every 100 office
visits. Adjusting for demographic mix, the estimated real-world CE improved be-
tween 2000 and 2001 by 16% ($25,000 per QALY vs. $21,000, respectively). From 1998
to 2008, the CE ratio fell by 23%. CONCLUSIONS: These results demonstrate that
cost-effectiveness projected at launch may provide only limited indication of the ul-
timate real-world impact, which improved substantially over time, in this example.
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OBJECTIVES: To evaluate and compared the long-term costs and outcomes of four
warfarin treatment strategies of CYP2C9, VKORC1, both CYP2C9 and VKORC1 gen-
otype-guided dosing, and standard warfarin dosing among nonvalvular VTE pa-
tients in the societal perspective. METHODS: A discrete event simulation model
was used to depict patients’ health states as the disease evolves with time, and
captured its associated costs (2007 U.S. dollars) and quality of life. Data was extrap-
olated with the criteria of including VTE patients of age 18 years on warfarin
with INR target of 2-3. Probabilities, costs and humanistic properties were obtained
from the literature, HCUP (NIS & SEDD), and the Medicare Reimbursement Sched-
ule databases. Sensitivity analysis was performed for uncertainty parameters in
the model. All costs and benefits were discounted at 3%. RESULTS: There was a
significant difference in the prevalence of bleeding complication between standard
anticoagulation (6.1%) and the genotype –guided of CYP2C9 and VKORC1 groups
(5.8%). The mean cost and QALYs per patients were $14,340 and 8.1251. The
genotype-guided warfarin anticoagulation strategies projected higher cost and
higher QALYs. However, considering the threshold of $100,000/QALY, VKORC1 gen-
otype-guided was indicated to be cost-effective among all strategies. Sensitivity
analysis demonstrated 25% of the replications of both CYP2C9 and VKORC1 geno-
type-guided strategy to be $100,000/QALY. CONCLUSIONS: This study showed
that testing for multiple genotypes of CYP2C9 and VKORC1 to guide warfarin anti-
coagulation therapy is not cost –effective in all population and that patient with
higher risk of complications are more likely to benefit from this new innovation.
For the genotype-guided test to be cost-effective in the population with VTE, the
cost of the test would have to be $400 or be restricted to patient at high risk for
bleeding complications (RR5.8).
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OBJECTIVES: The PLATO trial showed that in patients with acute coronary syn-
dromes (ACS) treatment with ticagrelor compared with clopidogrel significantly
reduced the rate of myocardial infarction (MI), stroke, or death from vascular
causeswithout a significant increase in the rate of overallmajor bleeding. Based on
clinical and health-economic data from PLATO the present study evaluates the
long-term cost-effectiveness of treating patients with ticagrelor based on the EU
label.METHODS: A two-part decision-analytic model, comprising a one-year deci-
sion tree and a long-termMarkovmodel, was constructed to estimate lifetime costs
and QALYs of treating ACS patients for one year with ticagrelor plus acetylsalicylic
acid (ASA) comparedwith clopidogrel plus ASA. Using individual-patient data from
PLATO, event rates, health-care costs (Swedish in base-case analysis), and QALYs
were estimated for the first year. For the second year onwards, necessary assump-
tions and external data sources were utilized to extrapolate quality-adjusted sur-
vival conditional onwhether a non-fatalMI, a non-fatal stroke or no event occurred
during the first year. A probabilistic analysis was performed and incremental cost-
effectiveness ratios are presented from a health-care perspective in 2010 prices. A
generic clopidogrel price of €0.17 ($0.23) per day, and a ticagrelor price range of €2.25
($3.00) to €3.50 ($4.65) per day were applied. RESULTS: Treatment with ticagrelor
was associated with a QALY gain of 0.13 compared with clopidogrel. The cost per
QALY gained with ticagrelor was in the range of €2,350 ($3,110) to €5,700 ($7,550)
compared with clopidogrel. Ticagrelor is likely to be cost-saving if proprietary
clopidogrel prices are applied. The results were consistent in major sub groups
across the broad ACS population. CONCLUSIONS: Based on clinical and health-
economic evidence from the PLATO study, treating a broad spectrum of ACS pa-
tients with ticagrelor for one year based on the European label is cost-effective
compared with clopidogrel.
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OBJECTIVES: Associated use of antithrombotics, antiplatelets and invasive strate-
gies in patients with non ST-segment elevation acute coronary syndromes (NSTE-
ACS) reduces cardiovascular events, however, with an increase in the risk of bleed-
ing. Clinical studies showed that fondaparinux is as effective as enoxaparin in
treating patients with NSTE-ACS, but with reduced risk of bleeding events. The
objective was to determine the cost-effectiveness of fondaparinux versus enoxa-
parin in patients with NSTE-ACS in Brazil from the perspective of the Brazilian
Ministry of Health (MoH). METHODS: An analytic decision tree model was con-
ducted to estimate the resultant costs and consequences of the targeted therapies
in patients with NSTE-ACS. Model input data derived from the OASIS-5 study
(N20,078 NSTE-ACS patients randomized to fondaparinux or enoxaparin). The
analyzed outcome was a composite of cardiovascular events (i.e., death, acute
myocardial infarction, stroke, and major bleedings). Model time horizon was 9, 30,
and 180 days post-NSTE-ACS. Direct costs of NSTE-ACS events and treatments
were computed (i.e., drugs, coronary angiography, myocardial revascularization,
percutaneous intervention - PCI, hospitalizations, etc.). Costs were expressed in
2010 Brazilian currency (1BRL0.59USD). Univariate andmultivariate (Monte Carlo)
analyses tested model robustness. RESULTS: At day 9, the average cost per patient
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